ClearMed
BriefingsDrug & Biomarker IndexSaved (0)
All Oncology BriefingsCancer Discovery
OncologyClinical Practice2 min read

New ADC Approaches Aim to Broaden Target Coverage

The antibody-drug conjugate field is increasingly looking to go after more than one target at a time.

Published in Cancer DiscoveryClinical evidence review
3/5 Observational
Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

Source

Real-World Observation

3/5

As well, two bispecific ADCs, respectively targeting -c-MET and -B7-H3, appear active against multiple solid tumor types.

What Changes?

Oncology · Clinical Practice

Current Standard

Conventional oncology practice relies on standard-of-care monitoring and existing regimens prior to this clinical evidence review.

New Finding

Preliminary (real-world effectiveness in the trial) data suggest that B7-H3-targeting elfetabart drozuntecan plus the PD-L1-VEGF-A bispecific pumitamig could be a potential combination strategy.

3 Key Takeaways

Plain English Summary
  1. 01Core Finding

    Delivered via new ADC Approaches Aim to Broaden Target Coverage, this clinical practice approach targets Antibodies.

  2. 02Study Evidence

    Study design used a clinical evidence review protocol to track clinical outcomes.

  3. 03Practical Meaning

    Benefits and risks vary by individual health history — discuss with a healthcare professional.

What This Means for You

As well, two bispecific ADCs, respectively targeting -c-MET and -B7-H3, appear active against multiple solid tumor types.

The Discovery

The antibody-drug conjugate field is increasingly looking to go after more than one target at a time. Preliminary (real-world effectiveness in the trial) data suggest that B7-H3-targeting elfetabart drozuntecan plus the PD-L1-VEGF-A bispecific pumitamig could be a potential combination strategy.

How It Works, Simply

This oncology research focuses on antibodies. Researchers evaluated it using a standard-of-care clinical practice · Clinical evidence review at the clinical practice stage of medical research.

3 Key Takeaways

Clinical Takeaways
  1. 01Core Finding

    Delivered via new ADC Approaches Aim to Broaden Target Coverage, this clinical practice approach targets Antibodies.

  2. 02Study Evidence

    Study design used a clinical evidence review protocol to track clinical outcomes.

  3. 03Practical Meaning

    Benefits and risks vary by individual health history — discuss with a healthcare professional.

01

Biological Mechanism & Study Design

Study Design & Cohort

Clinical evidence review

Standard-of-care clinical practice · Clinical evidence review · Clinical Practice

Biological Pathway & Modality

Antibodies

Intervention: New ADC Approaches Aim to Broaden Target Coverage

02

Experimental Findings & Endpoints

The antibody-drug conjugate field is increasingly looking to go after more than one target at a time.

Preliminary data suggest that B7-H3-targeting elfetabart drozuntecan plus the PD-L1-VEGF-A bispecific pumitamig could be a potential combination strategy.

03

Clinical Translation & Practice Context

As well, two bispecific ADCs, respectively targeting -c-MET and -B7-H3, appear active against multiple solid tumor types.

03

The Bottom Line · Clinical Pearl

“As well, two bispecific ADCs, respectively targeting EGFR-c-MET and EGFR-B7-H3, appear active against multiple solid tumor types.”

Published in Cancer Discovery · Current Stage: Clinical Practice

Practical Next Step

Questions for Your Next Doctor Visit

  1. 1Based on my health history, do these oncology findings (standard-of-care clinical practice · Clinical evidence review in oncology care) apply to my situation?
  2. 2How do the potential benefits of this approach compare with the standard care I'm currently using?
  3. 3Given the study's key limitation (benefits and risks vary by individual health history — discuss with a healthcare professional.), what risks or follow-up steps should we watch for?
Oncology · Clinical Practice
Study Type
Clinical evidence review

Standard-of-care clinical practice · Clinical evidence review

Evidence Score
3/5 · Real-World Observation
Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

Who It Applies To
Standard-of-care clinical practice · Clinical evidence review in oncology care
Intervention & Mechanism
New ADC Approaches Aim to Broaden Target Coverage

Antibodies

Key Limitation
Benefits and risks vary by individual health history — discuss with a healthcare professional.

Translational Stage

LEVEL 1 · Clinical Practice

Classified as Clinical evidence review along the clinical evidence continuum

  1. Lab & Discovery
  2. Early Trials
  3. Human Evidence
  4. 4Clinical PracticeActive

Indexed Clinical Entities

Immune Checkpoint InhibitorsMonoclonal Antibodies & BiologicsKRAS, EGFR & BRCA OncogeneseGFR, Albuminuria & Renal Function

Original Publication & AMA Citation

New ADC Approaches Aim to Broaden Target Coverage. Cancer Discovery. Published 2026;Oct 26. Accessed November 15, 2026. https://pubmed.ncbi.nlm.nih.gov/42932175/

Cancer Discovery

https://pubmed.ncbi.nlm.nih.gov/42932175/

Read Original Paper

Continue Reading

Related in Oncology

View all Oncology briefings →
ONCOLOGY · CLINICAL PRACTICE

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial

In this interim analysis, short-course radiotherapy followed by camrelizumab and CAPOX significantly improved 3-year event-free survival in patients with locally advanced rectal cancer, with a safety profile similar to long-course chemoradiotherapy followed by CAPOX. Comparison of this promising new treatment strategy with contemporary total neoadjuvant therapy strategies is warranted.

5/5 Gold Standard
Evidence Meter · 5/5

Gold-Standard Human Evidence

Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.

1 min readThe Lancet Oncology
ONCOLOGY · REAL-WORLD COHORT

Curative-intent management of de novo metastatic nasopharyngeal carcinoma: an evidence-based consensus guideline from the International Collaborating Oncology Organisations

This guideline provides a practical framework for standardisation of clinical management of de novo metastatic nasopharyngeal carcinoma and identification of key evidence gaps for future research. We recommend that curative-intent treatment should be offered to medically fit patients with no more than three metastatic lesions in two or fewer organs at baseline or following response to systemic therapy; multimodality treatment (comprising immunochemotherapy, locoregional radiotherapy, metastasis-directed therapy, and maintenance therapy) is recommended.

3/5 Observational
Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readThe Lancet Oncology
ONCOLOGY · REAL-WORLD COHORT

Development of the Children's Oncology Group long-term follow-up guideline for cancer genetics evaluation in childhood cancer survivors

Raising awareness of this guideline is crucial to enhancing the integration of genetics into survivorship care and improving health outcomes for childhood cancer survivors with CPS. This Policy Review details the importance, development, and anticipated impact of this new guideline.

3/5 Observational
Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readThe Lancet Oncology